Dr. Gregory Vidal, M.D
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Tulane University School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 768
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2008Medical school: Tulane University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TN license 51775 · MS license 23969
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
- Regional One Health Memphis, TN
- St Francis Hospital Memphis, TN
Medical groups
- The West Clinic P.c. (118 clinicians)
- Shelby County Health Care Corporation (40 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 768
- Services billed
- 144,187
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 2,015 | 11 |
| Injection, denosumab, 1 mg | 1,200 | 13 |
| Injection, dexamethasone sodium phosphate, 1 mg | 816 | 50 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 596 | 196 |
| Blood test, basic group of blood chemicals (calcium, total) | 559 | 191 |
| Liver function blood test panel | 498 | 171 |
| Insertion of needle into vein for collection of blood sample | 445 | 162 |
| Established patient office or other outpatient visit, 30-39 minutes | 442 | 217 |
| Injection, leucovorin calcium, per 50 mg | 218 | 12 |
| Injection, palonosetron hcl, 25 mcg | 210 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Germantown, TN | 463 |
| Letrozole Other prescribers in Germantown, TN | 247 |
| Tamoxifen Citrate Other prescribers in Germantown, TN | 209 |
| Verzenio (abemaciclib) | 125 |
| Ibrance (palbociclib) | 95 |
| Exemestane | 92 |
| Potassium Chloride Other prescribers in Germantown, TN | 69 |
| Gabapentin Other prescribers in Germantown, TN | 61 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Germantown, TN | 57 |
| Ondansetron Hcl Other prescribers in Germantown, TN | 54 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 15 companies reported 111 payments worth $79,556 in total to this clinician.
| Gilead Sciences, Inc. | $21,300 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $15,950 |
| Genentech, Inc. | $12,092 |
| Novartis Pharmaceuticals Corporation | $9,992 |
| Eli Lilly and Company | $8,400 |
| Tersera Therapeutics LLC | $4,784 |
| Lilly USA, LLC | $2,400 |
| Pfizer Inc. | $2,313 |
| Consulting Fee | $51,236 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $17,550 |
| Travel and Lodging | $6,357 |
| Food and Beverage | $3,364 |
| Long term medical supply or device loan | $1,049 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,750 |
| Gilead Sciences, Inc. Mar 19, 2025 | Consulting FeeCompany’s description;4275666;VEM US;11166271 | $6,100 |
| Eli Lilly and Company Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,600 |
| Novartis Pharmaceuticals Corporation Nov 10, 2025 | Consulting Fee KISQALI · Oncology | $5,300 |
| AstraZeneca Pharmaceuticals LP Jul 14, 2025 | Consulting Fee | $3,200 |
| Tersera Therapeutics LLC May 31, 2025 | Consulting Fee Zoladex · Oncology | $3,000 |
| Gilead Sciences, Inc. May 7, 2025 | Consulting Fee Trodelvy · ONC Company’s description;3978975;SAP;11166271 | $2,910 |
| Genentech, Inc. Jun 4, 2025 | Consulting Fee | $2,813 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $2,408 |
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee ENHERTU · Oncology | $2,400 |
All 59 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Dec 19, 2025 | Consulting Fee ENHERTU · Oncology | $2,400 |
| Eli Lilly and Company Dec 16, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,600 |
| Genentech, Inc. Dec 12, 2025 | Compensation for services other than consulting (speaking, faculty) | $6,750 |
| Gilead Sciences, Inc. Dec 9, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4290553;GTF;11166271 | $726 |
| Gilead Sciences, Inc. Nov 30, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289902;GTF;11166271 | $726 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Nov 10, 2025 | Consulting Fee KISQALI · Oncology | $5,300 |
| AstraZeneca Pharmaceuticals LP Nov 10, 2025 | Consulting Fee ENHERTU · Oncology | $800 |
| Gilead Sciences, Inc. Nov 6, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4267684;VEM US;11166271 | $1,090 |
| Gilead Sciences, Inc. Oct 23, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4253409;VEM US;11166271 | $1,820 |
| AstraZeneca Pharmaceuticals LP Oct 23, 2025 | Consulting Fee DATROWAY · Oncology | $800 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Oct 20, 2025 | Consulting Fee | $2,400 |
| Gilead Sciences, Inc. Oct 18, 2025 | Travel and Lodging Trodelvy · ONC · travel to Foster City, CA · in-kind Company’s description;4253562;VEM US;11166271 | $634 |
| Novartis Pharmaceuticals Corporation Oct 6, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to Fort Lauderdale, FL · in-kind | $758 |
| Novartis Pharmaceuticals Corporation Oct 6, 2025 | Travel and Lodging KISQALI · Oncology · travel to Fort Lauderdale, FL | $679 |
| Gilead Sciences, Inc. Sep 30, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289897;GTF;11166271 | $726 |
| Genentech, Inc. Sep 22, 2025 | Consulting Fee | $665 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Eli Lilly and Company Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $5,600 |
| Eli Lilly and Company Sep 9, 2025 | Compensation for services other than consulting (speaking, faculty) | $1,200 |
| AstraZeneca Pharmaceuticals LP Sep 6, 2025 | Consulting Fee | $800 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Gilead Sciences, Inc. Aug 19, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4289899;GTF;11166271 | $726 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Consulting Fee | $800 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Pfizer Inc. Jul 24, 2025 | Consulting Fee IBRANCE · ONCOLOGY | $2,160 |
| Gilead Sciences, Inc. Jul 15, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4252166;GTF;11166271 | $1,452 |
| AstraZeneca Pharmaceuticals LP Jul 14, 2025 | Consulting Fee | $3,200 |
| AstraZeneca Pharmaceuticals LP Jul 8, 2025 | Consulting Fee | $1,070 |
| AstraZeneca Pharmaceuticals LP Jun 24, 2025 | Consulting Fee | $800 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Genentech, Inc. Jun 4, 2025 | Consulting Fee | $2,813 |
| Tersera Therapeutics LLC May 31, 2025 | Consulting Fee Zoladex · Oncology | $3,000 |
| Tersera Therapeutics LLC May 31, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA | $214 |
| Novartis Pharmaceuticals Corporation May 30, 2025 | Consulting Fee KISQALI · Oncology | $2,100 |
| Tersera Therapeutics LLC May 25, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $427 |
| Tersera Therapeutics LLC May 25, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $67.14 |
| Tersera Therapeutics LLC May 25, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $46.62 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Gilead Sciences, Inc. May 7, 2025 | Consulting Fee Trodelvy · ONC Company’s description;3978975;SAP;11166271 | $2,910 |
| Lilly USA, LLC Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) VERZENIO · Oncology | $2,400 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Apr 14, 2025 | Consulting Fee DATROWAY · Oncology Company’s descriptionResearch Related Service | $2,408 |
| Gilead Sciences, Inc. Apr 4, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4252153;GTF;11166271 | $870 |
| Gilead Sciences, Inc. Apr 4, 2025 | Consulting Fee Trodelvy · ONC Company’s description;4250506;GTF;11166271 | $580 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| Genentech, Inc. Mar 20, 2025 | Travel and Lodging travel to South San Francisco, CA · in-kind | $568 |
| Genentech, Inc. Mar 20, 2025 | Travel and Lodging travel to South San Francisco, CA · in-kind | $565 |
| Genentech, Inc. Mar 20, 2025 | Travel and Lodging travel to South San Francisco, CA | $248 |
| Gilead Sciences, Inc. Mar 19, 2025 | Consulting FeeCompany’s description;4275666;VEM US;11166271 | $6,100 |
| Tersera Therapeutics LLC Mar 7, 2025 | Travel and Lodging Zoladex · Oncology · travel to Plymouth Meeting, PA · in-kind | $757 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
| AstraZeneca UK Limited Feb 20, 2025 | Consulting Fee | $1,995 |
| Gilead Sciences, Inc. Jan 30, 2025 | Travel and Lodging travel to Las Vegas, NV Company’s description;4275679;VEM US;11166271 | $50.00 |
| Gilead Sciences, Inc. Jan 27, 2025 | Travel and Lodging travel to Las Vegas, NV · in-kind Company’s description;4275674;VEM US;11166271 | $852 |
| Gilead Sciences, Inc. Jan 27, 2025 | Travel and Lodging travel to Las Vegas, NV · in-kind Company’s description;4275667;VEM US;11166271 | $490 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $99.70 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 21 industry-funded studies in 2025, from 10 companies. The companies reported $3,241,034 in research payments for these studies, mostly to the institutions running them.
- Study name not reported
GlaxoSmithKline, LLC. - BNT327-02
BioNTech SE - Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients
Genentech, Inc. - Morpheus Breast Cancer
Hoffmann-la Roche Limited - A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab MK-3475 Versus Treatment of Physician s Choice TPC in Participants With Triple-Negative…
Merck Sharp & Dohme LLC - BNT327
BioNTech SE - MORPHEUS TNBC
Hoffmann-la Roche Limited - A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT05514054 - A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - T DM1 Atezolizumab in high risk HER2 patients with residual disease
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.